China Life Insurance (SEHK:2628) Signs New Sales Deal As Fair Value Still Looks Higher
China Life Insurance (SEHK:2628) drew investor attention after announcing a new multi year Insurance Sales Framework Agreement with China Life Property and Casualty. The agreement covers a wide mix of products and sets higher agency fee caps through 2029.
See our latest analysis for China Life Insurance.
The new framework agreement lands against a backdrop of steady gains for China Life Insurance, with the latest share price at HK$29.2 and a 1-year total shareholder return of 36.94% and 5-year total shareholder return of 180.58%, which points to momentum that investors are still pricing in positively.
If this type of insurance partnership has caught your attention, it can be worth widening your watchlist to see which other companies stand out through our 106 top founder-led companies
China Life Insurance now trades at HK$29.2, while analyst targets and intrinsic value estimates sit higher. The gap is wide enough to matter. Where does fair value really land within that spread?
Most Popular Narrative: 16% Undervalued
China Life Insurance’s most followed narrative points to a fair value of HK$34.77 per share, compared with the latest HK$29.2 price that investors see on screen.
The analysts have a consensus price target of HK$34.77 for China Life Insurance based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$44.61, and the most bearish reporting a price target of just HK$14.01.
Want to understand why this narrative still sees upside even with modest earnings expectations? The key is how revenue growth, margins and valuation multiples fit together.
Result: Fair Value of HK$34.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, China Life Insurance still faces questions around interest rate pressures on investment returns, as well as the risk that higher training costs could weigh on margins if productivity gains falter.
Find out about the key risks to this China Life Insurance narrative.
Next Steps
If this mix of opportunities and risks around China Life Insurance leaves you undecided, it may help to review the full picture and then move quickly to form your own view with the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond China Life Insurance?
If you stop with China Life Insurance, you may miss other stocks that match your style. Use targeted screeners now to spot ideas before everyone else.
- Target potential growth stories early by scanning 221 elite penny stocks with strong financials that already show stronger balance sheets and more resilient financial profiles.
- Focus on price and quality together by checking the 257 high quality undervalued stocks that pair solid fundamentals with share prices that still sit below many fair value estimates.
- Prioritise resilience by reviewing the 304 resilient stocks with low risk scores which filters for companies with steadier risk profiles that may better suit cautious portfolios.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com